TKT and prostate carcinoma: Domińska et al. observed that steroid hormones, testosterone, and 17β-estradiol were capable of reversion of the action of Ang II and Ang 1-7, which decreased protein TK activity in the late-stage prostate cancer cell line—DU145 [84].